Laboratory of Nutrition Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Steroid Biochem Mol Biol. 2021 Sep;212:105925. doi: 10.1016/j.jsbmb.2021.105925. Epub 2021 Jun 3.
There is some evidence for ameliorating effect of vitamin D on glycemic and lipidemic status which are likely to be mediated through other molecules including adiponectin. However, the overall results have been controversial. This study was conducted to evaluate the effect of vitamin D supplementation on serum adiponectin concentration. MEDLINE, PubMed, Embase, Cochrane Library, and Google Scholar were searched and 402 studies were found in a preliminary search. After screening of titles and abstracts nine studies were selected. Pooled data showed no significant effect on adiponectin concentrations (mean difference (MD) 0.37, 95 % CI: -0.1 to 0.87). However, there was a significant effect in a subgroup of participants who had diabetes (MD: 0.03, 95 % CI: 0.00 to 0.05, p = 0.029). The treatment effect on adiponectin concentrations was significant in those trials that used supplementation on a daily basis (MD: 0.03, 95 % CI: 0.00 to 0.05, p = 0.028) and vitamin D plus calcium (MD: 0.04, 95 % CI: 0.01 to 0.07, p = 0.014). The meta-regression revealed a significant association between BMI and age of participants at baseline and the treatment effect (B, -0.144, 95 % CI: -0.276 to -0.011, p = 0.033 and B, -0.043, 95 % CI: -0.075 to -0.012, p = 0.006). The results of this meta-analysis study indicates that vitamin D may be considered an adiponectin secretagogue in subjects with diabetes and this effect may be potentiated if vitamin D intake is on daily basis and in combination with calcium but can be weakened by increasing BMI.
有一些证据表明维生素 D 可以改善血糖和血脂状态，这可能是通过其他分子介导的，包括脂联素。然而，总体结果仍存在争议。本研究旨在评估维生素 D 补充对血清脂联素浓度的影响。我们检索了 MEDLINE、PubMed、Embase、Cochrane 图书馆和 Google Scholar，并在初步检索中发现了 402 项研究。经过标题和摘要筛选，选择了 9 项研究。汇总数据显示，脂联素浓度无显著变化（平均差异（MD）0.37，95%置信区间：-0.1 至 0.87）。然而，在患有糖尿病的亚组参与者中，存在显著影响（MD：0.03，95%置信区间：0.00 至 0.05，p=0.029）。在每日补充的试验中，维生素 D 对脂联素浓度的治疗效果显著（MD：0.03，95%置信区间：0.00 至 0.05，p=0.028），以及维生素 D 加钙（MD：0.04，95%置信区间：0.01 至 0.07，p=0.014）。Meta 回归显示，参与者的 BMI 和基线时的年龄与治疗效果之间存在显著关联（B，-0.144，95%置信区间：-0.276 至 -0.011，p=0.033 和 B，-0.043，95%置信区间：-0.075 至 -0.012，p=0.006）。本荟萃分析研究的结果表明，维生素 D 可能被认为是糖尿病患者的脂联素分泌激动剂，如果维生素 D 摄入是每日的，并与钙结合，这种作用可能会增强，但如果 BMI 增加，这种作用可能会减弱。
